Table 2.
Bloodstream infection characteristics
| N = 49 | |
|---|---|
| Age, median (IQR) | 67 (50–75) |
| Male, n (%) | 36 (73.5) |
| Charlson index, n (%) | 2 (1–4) |
| Type of infection, n (%) | |
| Complicated bloodstream infection | 34 (69.4) |
| Uncomplicated bloodstream infection | 15 (30.6) |
| Causative organism, n (%) | |
| MSSA | 15 (30.6) |
| MRSA | 9 (18.4) |
| CNS | 17 (34.7) |
| E. faecalis | 1 (2) |
| E. faecium | 2 (4.1) |
| Streptococcus | 2 (4.1) |
| Other | 1 (2) |
| No isolation | 2 (4.1) |
| Days of prior AB therapy, median (IQR) | 8 (0–15) |
| Prior antibiotic therapy, n (%) | 46 (93.9) |
| Daptomycin | 22 (44.9) |
| Ceftriaxone | 10 (20.4) |
| Linezolid | 9 (18.4) |
| Vancomycin | 11 (22.4) |
| Reason for DBV administration, n (%) | |
| Facilitate discharge | 38 (77.6) |
| Prior treatment failure | 1 (2) |
| Toxicity | 2 (4) |
| DBV dose, n (%) | |
| 1000 mg (1 day), 500 mg (8 days) | 14 (28.6) |
| 1000 mg 1 day | 11 (22.4) |
| 1500 mg 1 day | 21 (42.9) |
| Other | 3 (6.1) |
| DBV-covered treatment days (IQR) | 14 (14) |
| Clinical cure, n (%) | 49 (100) |
| Microbiological cure | |
| Follow-up blood cultures, n (%) | 36 (73.5) |
| Negative follow-up blood cultures | 35 (97.2) |
| Death related to bloodstream infection, n (%) | 0 |
| Relapse, n (%) | 0 |
| Readmission for different reason | 1 (2) |
| Reduction in days of hospital stay (IQR) | 14 (7–14) |
| Total reduction, days | 636 |